Tocagen Inc.

We are driven by a vision to end cancer mortality. Our company was founded on this vision in 2007. Tocagen’s mission is to become a leading biopharmaceutical company for the treatment of cancer using cancer-selective gene therapy products based on our retroviral gene therapy platforms to increase lifespan, initially for patients with advanced local and metastatic cancer. Our broadly applicable product candidates are designed to activate a patient’s immune system against their cancer from within. At the core of our approach is a novel gene therapy platform that utilizes retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the DNA of cancer cells. Our proprietary platform is designed to fight cancer through a combination of mechanisms of action without the autoimmune toxicities that patients commonly experience with other treatments. In other words, our technology is designed to combat cancer with fewer side effects, keeping patients’ healthy tissue intact while the tumor is destroyed. We believe Tocagen’s approach to fighting cancer using RRVs is an important scientific advancement over prior gene therapy approaches, as well as a potential complement to existing therapies. We believe our innovations may fulfill the promise of gene therapy as a safe and effective treatment for cancer. Ultimately, Tocagen exists for the patients, powered by a mission to revolutionize cancer treatment. With the right therapeutic approach, our hope is that even the most aggressive forms of cancer can be safely and effectively controlled, and each day we strive to turn that bold vision into reality.